|Intra-Individual Variation and Reliability of Biomarkers of the Antioxidant Defense System by Considering Dietary and Lifestyle Factors in Premenopausal Women||Lipid soluble biomarkers of the antioxidant defense system, such as plasma α-carotene, plasma β-carotene and coenzyme Q10 as well as eGPx are the most reliable biomarkers, whereas glutathione and TEAC exhibit the poorest reliability owing to their very low inter-individual variance in this study population. Q10 was measured with Chromsystems HPLC assay.||2021|
|Inflammatory biomarkers in patients in Simvastatin treatment: No effect of co-enzyme Q10 supplementation||Simvastatin therapy has beneficial effects on inflammatory markers in plasma, but CoQ10 supplementation seems to have no additional potentiating effect in patients in primary prevention. In contrast, glucose homeostasis may improve with CoQ10 supplementation. Q10 measured with Chromsystems assay.||2019|
|Recessive Dystonia-Ataxia Syndrome in a Turkish Family Caused by a COX20 (FAM36A) Mutation||The authors extend the phenotypic spectrum of a recently identified mutation in COX20 to a recessively inherited, early-onset dystonia-ataxia syndrome that is characterized by reduced complex IV activity. Further, they confirm a pathogenic role of this mutation in cerebellar ataxia, but this mutation seems to be a rather rare cause. Q10 measured with Chromsystems assay.||2014|
|The Relationships Between Clinical Outcome and the Levels of Total Antioxidant Capacity (TAC) and Coenzyme Q (CoQ 10) in Children With Pandemic Influenza (H 1 N1) and Seasonal Flu||Pandemic influenza infection had increased oxidative stress compared to the seasonal influenza. Q10 was measured with Chromsystems assay.||2012|
|Lower plasma Coenzyme Q10 in depression:a marker for treatment resistance and chronicfatigue in depression and a risk factor tocardiovascular disorder in that illness||The findings that lower CoQ10 is a risk factor to coronary artery disease and
chronic heart failure (CHF) and mortality due to CHF suggest that low CoQ10 is
another factor explaining the risk to cardiovascular disorder in depression. Q10 was measured by Chromsystems assay.
|The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene||We suggest to give patients both CoQ10 and riboflavin supplementation, especially for long-term treatment of Q10 deficiency. Q10 measured with Chromsystems assay.||2007|
Please find here publications as guides for reference ranges or therapeutic ranges. They may differ from other published data and are only intended to serve as a rough guide. As data vary depending on patient population and measurement method, please determine ranges for your laboratory. When determining ranges make sure that you comply with local national requirements.